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Abstract
Polycomb group (PcG) genes are responsible for main-
tenance of cellular identity and contribute to regulation
of the cell cycle. Recent studies have identified several
PcG genes as oncogenes, and a role for PcG proteins
in human oncogenesis is suspected. We investigated
the expression of BMI-1 and EZH2 PcG oncogenes
in human bronchial squamous cell carcinomas
(SCCs) and bronchial premalignant precursor lesions
(PLs). Whereas normal bronchial epithelium was as-
sociated with widespread expression of BMI-1 in
resting EZH2-negative cells, neoplastic cells in lung
carcinomas displayed altered expression of both BMI-1
and EZH2. Two patterns of abnormal PcG expres-
sion were observed: increased expression of BMI-1
in dividing neoplastic cells of PLs and SCCs, and
enhanced expression of EZH2 and Ki-67 in BMI-1–
positive cells according to severity of the histopatho-
logic stage. We propose that altered expression of BMI-
1 and EZH2 is an early event that precedes high rates of
proliferation in lung cancer. Because PcG complexes
are normally involved in the maintenance of cell
characteristics, abnormal PcG expression may con-
tribute to loss of cell identity.
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Introduction
Lung cancer is the leading cause of cancer-related deaths in
the western world [1]. It is generally assumed that squa-
mous cell carcinoma (SCC) in the central lung devel-
ops in a stepwise manner from normal bronchial epithelium
to cancer through the accumulation of (epi)genetic alter-
ations [2]. Our understanding of the carcinogenic process is
continuously growing with new genes or classes of genes
discovered that are involved in carcinogenesis. Polycomb
group (PcG) genes form such a class of genes.
PcG genes have been identified in Drosophila mela-
nogaster as repressors of homeobox genes throughout
development [3]. Drosophila PcG genes are evolutionarily
conserved and several vertebrate homologues have been
identified. PcG proteins form heterogeneous multimeric protein
complexes [4]. Two distinct and evolutionary conserved PcG
complexes have been identified, consisting of various PcG
proteins and non-PcG proteins. The polycomb repressive com-
plex 1 (PRC1) maintenance complex contains the BMI-1, MEL-
18, RING1, HPH, and HPC PcG proteins, and the PRC2
initiation complex contains the EZH2, EED, YY1, and SUZ
[12] PcG proteins [4–16]. PcG complexes most likely regulate
gene activity by epigenetic mechanisms because they are
associated with histone deacetylases and methyltransferases
involved in chromatin modification [15,17–20]. Although PcG
genes are essential for embryogenesis, they continue to con-
tribute to the regulation of various processes in the adult,
including cell cycle and hematopoiesis [21–25].
The pivotal role of PcG genes in normal development is
underscored by studies of mice with altered PcG gene expres-
sion, which indicated that PcG genes are involved in carcino-
genesis. For instance, overexpression of Bmi-1 as a transgene
results in a high predisposition for B-cell and T-cell lymphomas
[26]. Similarly, binding partners of BMI-1 in the PRC1 complex,
including RING1 and HPC2, have also been associated with
malignant transformation [11,27]. PcG genes most likely con-
tribute to oncogenesis by interfering with cell cycle control
mechanisms. Bmi-1 was shown to be an upstream regulator
of the INK4a-ARF locus, and Bmi-1 overexpression results
in suppression of p16INK4a in various experimental settings
[28–30]. Recent work on components of the PRC2 complex
showed that EZH2 is capable of providing a proliferative
advantage to primary cells [31]. EZH2 is regulated by the
pRB–E2F pathway and appears essential for cellular prolifer-
ation [31]. Evidence is rapidly increasing that PcG genes are
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also associated with carcinogenesis in humans. Several
studies showed that BMI-1 is overexpressed in malignant
lymphomas, resulting in coexpression with EZH2 in cycling
neoplastic cells [32–36]. The observation that altered PcG
gene expression also occurs in solid tumors, including carci-
nomas from the lung [37], breast [38–41], prostate [42,43],
and colorectum [44], suggests that aberrant PcG expression
may be a mechanism of transformation that is shared by
various tumors. Given the role of PcG complexes in epige-
netic modification of target gene expression, altered expres-
sion of PcG genes may contribute to the observed epigenetic
modifications that occur in cancer cells (recently reviewed
in Ref. [45]).
In the current study, we aimed to find out at what stage the
expression patterns of BMI-1 and EZH2 are altered during
bronchial carcinogenesis. To that end, expression of these
PcG genes was analyzed in bronchial SCC and various
stages of premalignant lesions (PLs).
Materials and Methods
Human Tissues
Bronchial carcinomas and adjacent macroscopically normal
tissues Neoplastic tissues and adjacent macroscopically
normal bronchial tissues were obtained from patients who
underwent a surgical resection of a primary SCC of the
bronchus at the VU Medical Center. Tissue parts of the
tumor and tumor-distant, macroscopically normal bronchial
tissues were collected and bisected, after which one part was
formalin-fixed and paraffin-embedded, and the other part
snap-frozen. We selected seven patients who were not
pretreated by chemotherapy or radiotherapy prior to surgery.
At the time of surgical resection, patients with bronchial
SCC were aged 71 years (median; range 47–76 years).
The male:female ratio was 5:2. Consecutive 4-mm sections
were cut from formalin-fixed and frozen tissues, for both
histopathologic assessment and immunohistochemistry
(IHC; formalin-fixed tissue) and immunofluorescence (IF;
frozen tissue), respectively. After histologic examination,
tumor samples were all classified as moderately or poorly
differentiated SCC, and the normal samples as histomorpho-
logically normal.
Premalignant endobronchial lesions Patients without clini-
cally overt cancer who were at risk for developing bronchial
carcinoma were investigated using autofluorescence bron-
choscopy (AFB; Xillix Technologies Corporation, Richmond,
BC, Canada) in combination with conventional white light
bronchoscopy (WLB). Indications for performing AFB were
suspicion of lung cancer or follow-up of treated cancer in the
aerodigestive tract [46]. Paired biopsy materials were
obtained from each area, revealing abnormal autofluores-
cence. Biopsies were formalin-fixed and used for routine
histopathology, and snap-frozen in liquid nitrogen for IF. We
randomly selected 29 samples of 19 patients, covering the
spectrum of endobronchial PLs. At the time biopsies
were obtained, patients were aged 63 years old (median;
range 40–73 years). The male:female ratio was 16:3. Con-
secutive sections were stained in hematoxylin and eosin
(H&E) and a single pathologist (E. R.) examined the slides
to confirm their histopathologic diagnosis. The slides
were categorized as follows: normal (N; n = 3), hyperplasia
(H; n = 3), squamous metaplasia (SM; n = 2), mild dysplasia
(MiD; n = 7), severe dysplasia (SD; n = 13), and carcinoma
in situ (CIS; n = 1).
IHC
IHC was performed as described before [32,33,35,36,
41,47–49]. Briefly, sections were deparaffinized and rehy-
drated, and endogenous peroxidase was inhibited. For anti-
gen retrieval, slides were boiled in 0.01 M sodium citrate
buffer (pH 6.0) for 15 minutes. Primary antibodies were
applied following preincubation with normal swine serum
(1/:10 for EZH2), normal rabbit serum (1:50 for BMI-1),
and MIB-1/Ki-67) for 10 minutes. For IHC detection of the
PcG proteins BMI-1 and EZH2, slides were incubated with,
respectively, the 6C9 mouse monoclonal antiserum for
60 minutes at room temperature and the K538 rabbit poly-
clonal antiserum (1: 800) overnight at 4jC. The primary
antibody (Ab) (MIB-1; DAKO, Glostrup, Denmark) was used
against MIB-1/Ki-67 (further notified as Ki-67). Secondary
antisera used were a biotinylated rabbit antimouse (1:200) or
a biotinylated swine antirabbit (1:300). Following incubation
in streptavidin–biotin complex/horseradish peroxidase
(sABC-HRP) (1:1000), slides were incubated in biotinylated
tyramine for 10 minutes to enhance the signal. For the
detection of Ki-67, no signal enhancer was used. Incubating
the slides in sABC-HRP (1:100) completed the detection.
3,3V-Diaminobenzidine tetrahydrochloride (DAB) was used
for light microscopic visualization of the signal. Slides were
counterstained in hematoxylin for 40 seconds, dehydrated in
methanol, and finally covered. All washing steps of the slides
were performed using phosphate-buffered saline (PBS).
Slides processed in the same manner, using PBS instead
of the primary Ab, were considered as a negative control. A
tonsil specimen, in which both BMI-1 and EZH2 are present
[49,50], was included as a positive control for the IHC
procedure during each experiment. Photographs were taken
with a Zeiss Axiophot microscope (Zeiss, Oberkochen,
Germany) and digitized using an Agfa Duoscan scanner
(Agfa, Mortsel, Belgium).
IF
Immunofluorescent stainings were performed as de-
scribed before [32,33,35,41,48,50]. Briefly, 4-mm sections
were cut from frozen tissues and mounted on poly-L-lysine–
coated slides. Sections were fixed in 2% formaldehyde.
Following inhibition of endogenous peroxidase, slides were
preincubated with PBS containing 5% bovine serum albu-
min. For the detection of the PcG proteins, BMI-1, EZH2, and
Ki-67 slides were incubated, respectively, with 6C9, a mouse
IgG2b monoclonal Ab l K358 (1:100), a rabbit polyclonal Ab;
and MiB-1 (IgG1) overnight at 4jC. The BMI-1 Ab was
detected using biotinylated goat anti–mouse IgG2 antiserum
(1:100) followed by rhodamine–thyramine (RT) in ethanol
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(1:1000). The EZH2 Ab was detected using swine anti–
rabbit Ig fluorescein isothiocyanate (FITC) as secondary
step, followed by streptavidin Cy3 (1:300). Ki-67 Ab was
detected using biotinylated anti-IgG1 (1:100) followed by
streptavidin allophycocyanin (1:1000) All washing steps
were performed using PBS containing 0.1% saponin. Slides
processed in the same manner, using PBS instead of the
primary Ab, were considered as negative controls. A tonsil
was included as a positive control for the staining procedure
during each experiment [50]. After slides were covered,
sections were analyzed with a Leica DMR Confocal Laser-
scan Microscope (Leica, Rijswijk, The Netherlands). Photo-
graphs were taken of representative areas of the slide;
images were stored digitally at 1024 dpi and processed using
Corel Photopaint 8.
Results
IHC on Bronchial SCCs and Adjacent Normal Tissues
We started our analysis by IHC staining of tumor tissues
and morphologically normal tissues of tumor distant sites,
obtained from seven patients with bronchial SCC. BMI-1,
EZH2, and Ki-67 were exclusively detected as nuclear
staining of the epithelial cells. Representative examples of
BMI-1–positive and EZH2–positive immunostainings are
shown in Figures 1 and 2. Normal bronchial epithelia of all
seven tumor distant samples showed abundant expression
of BMI-1 (Figures 1A and 2B) and sporadic staining for Ki-67
(Figure 2C), suggesting that BMI-1 expression was primarily
associated with resting Ki-67–negative cells. Normal epithe-
lium contained sporadic EZH2-positive cells, which were
primarily associated with the basal layer (Figure 1B). The
corresponding SCC samples revealed staining for Ki-67 in
most of the nuclei of neoplastic cells (not shown). Six of the
seven SCCs displayed diffuse nuclear staining for BMI-1 in a
large proportion of the neoplastic cells. The remaining sam-
ple showed a weak nuclear staining for BMI-1 in the neo-
plastic cells. Furthermore, all except two SCCs showed
diffuse clear nuclear staining for EZH2. The two exceptions
included one sample with weak but diffuse nuclear EZH2
immunostaining and one sample that was EZH2-immuno-
negative. In one particular case (Figure 2), the transition from
normal bronchial epithelium to invasive carcinoma could be
observed. In this sample, expression of BMI-1 was abundant
in both normal epithelium and SCC. By contrast, EZH2 and
Ki-67 were not detected in the normal bronchial epithelium,
whereas EZH2/Ki-67 expression became evident in adja-
cent, noninvasive dysplastic nuclei, as well as in malignant
cells. These staining patterns collectively show that neoplas-
tic cells in SCC display increased expression of EZH2, and
that this coincides with the presence of Ki-67. In addition, the
immunohistochemical staining patterns suggest that prolif-
erating Ki-67–positive neoplastic cells in SCC have retained
expression of BMI-1, and that this PcG gene is coexpressed
with EZH2.
Immunofluorescent Staining on Bronchial SCCs and
Adjacent Normal Tissues
To confirm the coexpression of BMI-1 and EZH2 in the
nuclei of neoplastic cells of bronchial SCCs, IF double
stainings for BMI-1 and EZH2 were performed on frozen
Figure 1. Expression of BMI-1 and EZH2 in normal bronchial epithelium and bronchial carcinoma. (A and B) Normal bronchial epithelium. (C and D) Bronchial
carcinoma. Normal bronchial epithelium displays widespread expression of BMI-1 (A) and sporadic expression of EZH2 in the basal layer (BL). By contrast, both
BMI-1 (C) and EZH2 (D) are expressed in the majority of neoplastic cells in bronchial carcinoma. Note that healthy intraepithelial (IE) cells in normal epithelium
(A and B) and tumor-infiltrating lymphocytes (TILs) in bronchial carcinoma (C and D) are BMI-1–positive and EZH2–negative.
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cryosections that were available in six of the abovemen-
tioned SCCs (including five cases that revealed both BMI-1
and EZH2 expression, and the case that was BMI-1–positive
but EZH2-negative). The IF staining patterns confirmed the
results obtained by IHC: normal bronchial epithelial samples
showed widespread BMI-1 expression, whereas EZH2 pos-
itivity was rarely observed (Table 1) and not associated with
the presence of BMI-1. The IF staining on frozen tumor
samples showed colocalization of BMI-1 and EZH2 in the
same nuclei in four of six cases that were BMI-1–positive
and EZH2-positive by IHC. In one of these cases, EZH2
staining was less intense, which was in accordance with IHC
findings of this case. In two of the cases without colocaliza-
tion, only BMI-1 was detected by IF. In one of those cases,
EZH2 was detected by IHC immunostaining but not by IF
immunostaining. Representative IF staining patterns for
tumor samples are shown in Figure 3. We conclude that
expression of BMI-1 and EZH2 are separated in normal
bronchial epithelia (Table 1) and that BMI-1–positive neo-
plastic cells in SCC gain expression of EZH2.
Immunofluorescent Staining on Premalignant Endobronchial
Lesions
To determine at what stage in bronchial tumorigenesis the
expression of BMI-1 and EZH2 is altered, we performed IF
triple stainings for BMI-1 and EZH2 in conjunction with Ki-67
in an additional group of patients at varying stages of the
disease (Table 2). The proliferation marker was added to
identify the proliferative cell fraction in PLs. The biopsies
containing only normal bronchial epithelium (n = 3) showed a
similar staining pattern as the tumor distant normal samples
described above (i.e., positive staining for BMI-1 and infre-
quent detection of EZH2-positive cells) and occasional de-
tection of Ki-67 in cells that were negative for BMI-1 and
Figure 2. Expression of BMI-1, EZH2, and Ki-67 at the transition from normal bronchial epithelium to invasive cancer. BMI-1 expression (A) is detected throughout
the normal epithelium (NE) and in SCC. By contrast, EZH2 is undetectable in NE but widespread in SCC (B). A minority of the EZH2–positive cells in SCC appear
to express the proliferation marker Ki-67 (C). The transition of normal epithelium to SCC is indicated by (*) and coincides with the appearance of EZH2 expression
and the continued presence of BMI-1.
Table 1. Results of IHC and IF Stainings on SCC and IHC Stainings on Adjacent Normal Tissues.
Age (years) Histology SCC (F; cm) Sex BMI-1/EZH2 Expression
IHC in SCC IF in SCC IHC and IF in Adjacent
Normal Tissues
71 SCC 1 Male ±/+ +/ +/
67 SCC 4.5 Female +/+ +/+ +/
71 SCC 7 Male +/+ +/+ +/
73 SCC 4.5 Male +/ +/ +/
47 SCC 6 Male +/+ +/+ +/
48 SCC 4 Female +/± +/± +/
76 SCC 3 Male +/+ ND +/
IHC, immunohistochemistry; IF, immunofluorescence; SCC, squamous cell carcinoma; (+) positive staining; (±) weak staining; () negative staining.
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EZH2. Lesions classified as hyperplasia (n = 3) showed
positive staining for BMI-1 in two of three cases. In one
case, a coexpression with EZH2 was evident, whereas the
other two cases revealed absence of EZH2 IF staining. Ki-67
staining was detected only occasionally, and in none of the
lesions could colocalization of the PcG proteins with Ki-67 be
found. Two lesions that were classified as squamous meta-
plasia revealed no staining for BMI-1, but one of them was
EZH2-positive. Ki-67 staining was detected in the basal cell
layer only and revealed no colocalization with EZH2 in the
single case that showed EZH2 expression. Five of seven
lesions that were classified as mild dysplasia revealed
staining for BMI-1, whereas all seven lesions were EZH2-
positive. Four of the lesions showed clear BMI-1/EZH2
colocalization. Ki-67 was detected mainly in the lower third
of the epithelial cell layer. All seven lesions showed colocal-
ization of EZH2 with Ki-67, whereas a very few cells showed
colocalization of BMI-1 and Ki-67 in only three lesions. These
lesions revealed triple staining for BMI-1, EZH2, and Ki-67 in
the same nuclei. All of the 14 lesions that were classified as
severe dysplasia or carcinoma in situ had EZH2 expression,
12 of which also revealed positivity for BMI-1. All these
12 cases showed BMI-1/EZH2 colocalization. Ki-67 could
be found throughout the whole epithelial layer in all 14
lesions, although its IF staining was more pronounced in
the lower segments of the epithelium. Colocalization of EZH2
with Ki-67 was observed in all lesions, and coexpression of
BMI-1 and Ki-67 in the same nuclei was found in 10 of 14
lesions. If lesions showed colocalization of BMI-1 with Ki-67,
EZH2 was also expressed in the same nuclei. A represen-
tative example is shown in Figure 4. We conclude that EZH2
overexpression occurs at the level of PLs, which, in combi-
nation with disability to downregulate BMI-1, leads to coex-
pression. Furthermore, EZH2 expression appears to
precede increased proliferation in PLs.
Discussion
PcG genes play a key role in maintenance of cell identity, and
contribute to processes such as regulation of the cell cycle
and hematopoiesis. Their essential function in normal cellu-
lar development is reflected by the fact that abnormal PcG
gene expression is linked to carcinogenesis. In the current
paper, we analyzed the expression of the BMI-1 and EZH2
Figure 3. Coexpression of BMI-1 and EZH2 in bronchial carcinoma. Neoplastic cells in bronchial carcinoma (SCC) display widespread expression of BMI-1
(A; detected by red immunofluorescence) and EZH2 (B; detected by green immunofluorescence). Coexpression of BMI-1 and EZH2 in the same nucleus is indicated
by yellow fluorescence (C), resulting from combination of the individual signals for BMI-1 and EZH2. Note that TILs are BMI-1–positive and EZH2–negative.
Table 2. Results of IF Stainings on Biopsies of Histomorphologically Normal Bronchial Epithelial Samples and Premalignant Endobronchial Lesions (Positive
Lesions Per Histopathologic Diagnosis).
Histology BMI-1 EZH2 BMI-1  EZH2 EZH2  Ki-67 BMI-1  MIB BMI-1  EZH2  Ki-67
N (n = 3) 3/3 0/3 0/3 0/3 0/3 0/3
H (n = 3) 2/3 1/3 1/3 0/3 0/3 0/3
SM (n = 2) 0/2 1/2 0/2 0/2 0/2 0/2
MiD (n = 7) 5/7 7/7 4/7 7/7 3/7 3/7
SD/CIS (n = 14) 12/14 14/14 12/14 14/14 10/14 10/14
N, normal; H, hyperplasia; SM, squamous metaplasia; MiD, mild dysplasia; SD/CIS, severe dysplasia and/or carcinoma in situ.
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PcG oncogenes, representing the PRC1 PcG and PRC2
PcG complex, respectively. We discovered that bronchial
SCCs and their PLs are associated with two altered patterns
of PcG expression: the presence of BMI-1 protein in dividing
neoplastic cells, and increased expression of EZH2 resulting
in coexpression with BMI-1.
BMI-1 is abnormally expressed in neoplastic cells of
bronchial SCCs and PLs. Analysis of histologically normal
bronchial epithelium showed abundant expression of BMI-1
in epithelial cells, and that BMI-1 was primarily expressed in
resting Ki-67–negative cells. This pattern is reminiscent of
earlier studies of lymphocytes [48–50] and breast epithelia
[41], where resting cells preferentially express BMI-1. By
contrast, we found that cycling neoplastic cells in PL and
SCCs display an increasing frequency of BMI-1 expression:
in 43% of the mild dysplasias and 71% of the severe
dysplasias, BMI-1 was detected in proliferating cells. Given
the association of BMI-1 with resting cells in the normal
epithelium, we interpret this expression pattern as abnormal.
Experimental model systems convincingly demonstrated
that overexpression of BMI-1 is strongly associated with
increased cell proliferation and malignant transformation
through suppression of p16INK4a and upregulation of telo-
merase [28,29,38]. Our study fits well with abnormal BMI-1
expression patterns in lymphoid malignancies [32–36],
breast carcinoma [38,41], and colorectal carcinoma [44],
and supports the earlier observations that development of
lung carcinomas is associated with BMI-1 overexpression
and loss of p16INK4a expression [37]. The presence of BMI-1
in PLs suggests that BMI-1 expression in proliferating neo-
plastic cells is an early event in lung carcinogenesis.
Development of lung cancer is associated with enhanced
expression of the EZH2 PcG gene. In addition to the abnor-
mal expression pattern of BMI-1 in cycling neoplastic cells,
we also found an increased expression of the EZH2 PcG
gene in bronchial SCC and its PLs. Whereas EZH2 expres-
sion was rare in normal bronchial epithelia, EZH2 was
present in nonproliferating and cycling cells of all mildly—
and severely—dysplastic lesions. These findings are in line
with a recent study by Bracken et al. [31], who demonstrated
that EZH2 expression is moderately to strongly enhanced in
over 30% of primary human tumors. We found that the
proportion of EZH2-positive cells in proliferating cell fraction
increased with the severity of the histopathologic stage, and
that the majority of bronchial SCCs showed expression of
EZH2. Increased expression of EZH2 appears to be an early
event because EZH2 was detected in one hyperplasia and
one squamous metaplasia, and became predominantly man-
ifest in dysplastic tissues. EZH2 expression resulted in
coexpression with the BMI-1 PcG gene in neoplastic
cells—a pattern that was not observed in normal epithelia.
These observations collectively suggest that EZH2 expres-
sion in BMI-1–positive neoplastic cells is associated with the
development of lung cancer. Although EZH2 expression is
Figure 4. Expression of BMI-1, EZH2, and Ki-67 in severe dysplasia. Neoplastic cells in severe dysplasia display widespread expression of BMI-1 (A; detected by
red immunofluorescence), EZH2 (B; detected by green immunofluorescence), and Ki-67 (C; detected by blue fluorescence). Combination of signals for BMI-1,
EZH2, and Ki-67 (D) displays a diverse population of neoplastic cells with extensive fluctuation in gene expression. Note that the majority of the cells coexpresses
BMI-1 and EZH2, but that a subfraction of these appears to be in cycle (Ki-67–positive).
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linked to a variety of human epithelial tumors [31,40,42,
43,51], the mechanism responsible for enhanced expression
of EZH2 remains ill defined. EZH2 appears to be controlled
by the pRB pathway [31], which is frequently deregulated in
human tumors [52]. An additional possible mechanism that
may contribute to deregulation of EZH2 expression is ampli-
fication of the EZH2 gene, which was recently reported in up
to 15% of human cancers [31].
The question remains as to whether induction of EZH2 is
responsible for cellular transformation, or whether it is mainly
reflective of increased cell division. Current evidence sup-
ports both conclusions. Previous studies of lymphoid devel-
opment demonstrated that EZH2 expression is primarily
associated with cycling normal lymphocytes and proliferating
neoplastic cells [32–36,48–50]. A direct link between EZH2
expression and proliferation is further supported by experi-
mental suppression of EZH2, which resulted in diminished
proliferation of cell lines [31], whereas overexpression of
EZH2 resulted in enhanced proliferation rates [34]. In the
current work, we found that the EZH2 expression pattern of
histologically normal epithelia did not necessarily overlap
with Ki-67, and that a considerable proportion of nuclei in
PLs expressed EZH2 in the absence of Ki-67. These obser-
vations suggest that EZH2 expression in PLs precedes the
induction of proliferation during bronchial carcinogenesis, as
was recently observed in PLs of breast carcinomas [41]. To
what extent EZH2 expression is directly linked to cellular
transformation cannot be determined by the current study,
but the recent identification of EZH2 as a bona fide oncogene
suggests that EZH2 may directly contribute to lung carcino-
genesis and loss of cell identity [31]. Aside from being
essential for proliferation, our current work also suggests
that EZH2 expression is related to differentiation because
EZH2 was detected at the transition from normal and hyper-
plastic epithelium (both consisting of cylindrical type of
epithelium) to squamous metaplasia. Interestingly, en-
hanced expression of EZH2 in breast carcinomas is primarily
seen in ductal carcinoma in situ (DCIS) and carcinomas of
poor differentiation [41]. In the present study, all bronchial
SCCs were moderately or poorly differentiated, possibly
explaining the high proportion of SCCs with frequent EZH2
expression. Functional and follow-up studies are needed to
elucidate the precise role of EZH2 and other PcG genes in
bronchial carcinogenesis.
In conclusion, we showed that neoplastic cells in lung
carcinomas display altered expression of the BMI-1 and
EZH2 PcG genes. We propose that altered expressions of
BMI-1 and EZH2 are early events that precede high rates of
proliferation. Because PcG complexes are normally involved
in the maintenance of cell characteristics, abnormal expres-
sion of PcG genes may contribute to loss of cell identity.
Several members of the PcG gene family have been identi-
fied as oncogenes, and recent studies in humans demon-
strated that hematologic malignancies and solid tumors are
all linked to altered PcG gene expression. Collectively, these
studies strongly suggest that altered expression of PcG
genes is an important contributing factor in the development
of neoplasms in humans.
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